QUOTED. 6 May 2020. David Stavens.

Nines recently became the first company to gain 510(k) clearance from the US FDA to market an algorithm-based software solution called NinesAI that allows radiologists to triage intracranial hemorrhage and mass effect on CT scans from non-emergent cases. See what Nines’ CEO David Stavens said about it here.

Quoted

“It allows emergent cases to be seen faster, which improves the quality of care and also reduces the cost of care, because if emergencies are seen faster, they are more cost-effective to treat.” – David Stavens, CEO, Nines

Click here for a free trial of Medtech Insight

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Digital Technologies

More from Medtech Insight

With CMS Coverage Established, Medtronic Looks To Next Steps For Renal Denervation

 
• By 

US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the

House Bill Calls For ‘Non-Flushable’ Label On Personal Wipes

 

The US House of Representatives passes legislation requiring manufacturers of non-flushable wet wipes to label products as ‘non-flushable," a move endorsed by the Personal Care Products Council.

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.